Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Hemlibra (Emicizumab-kxwh)

October 11, 2018 Technology Prognosis

Hemlibra (emicizumab) is a bispecific monoclonal antibody that mimics the coagulation function of clotting factor VIII (FVIII). This “nonfactor” therapy bridges activated clotting factors IX and X, thereby fulfilling the role normally played by activated FVIII in the coagulation cascade.

Nuzyra (Omadacycline)

October 8, 2018 Technology Prognosis

Nuzyra (omadacycline) is an oral and intravenous aminomethylcycline antibiotic for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. It is designed to surmount certain forms of antibiotic resistance found in community-acquired infections.

Tegsedi (Inotersen)

October 8, 2018 Technology Prognosis

Inotersen is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.

Libtayo (Cemiplimab)

October 4, 2018 Technology Prognosis

Libtayo (cemiplimab) is an intravenous programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Epidiolex (Cannabidiol) for Epilepsy

September 28, 2018 Technology Prognosis

Epidiolex is an oral liquid formulation of a highly purified extract of cannabidiol (CBD). CBD is a non-psychoactive component of Cannabis sativa (marijuana). It is approved by the Food and Drug Administration for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age and older.